Recent Updates
Recently added Catalysts
HELP

Cybin to Announce Second Quarter FY2021 Financial Results and Business Update on

Key Takeaway: Cybin to Announce Second Quarter FY2021 Financial Results and Business Update on November 15, 2021 TORONTO, CANADA November 9, 2021 Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) ( Cybin or the Company ), a biopharmaceutical company focused on progressing Psychedelics to Therapeuti

Full Press Release Details

Cybin to Announce Second Quarter FY2021 Financial Results and Business Update on November 15, 2021
TORONTO, CANADA November 9, 2021 Cybin Inc. (NEO:CYBN) (NYSE American:CYBN)
( Cybin or the Company ), a biopharmaceutical company focused on progressing Psychedelics to TherapeuticsTM today announced that it will report
financial results for its second quarter of fiscal 2021 ended September 30, 2021 on Monday, November 15, 2021.
A conference call will be held
on the same day at 4:30 p.m. (EST) to discuss the results and recent business updates. The call will be hosted by Doug Drysdale, Cybin s Chief Executive Officer. Mr. Drysdale and other members of the management team will be available to
answer questions from participants following the prepared remarks.
CONFERENCE CALL DETAILS:
DATE: Monday, November 15, 2021
TIME: 4:30 p.m. (EST)
DIAL-IN 1-844-200-6205 (U.S. toll free) or 1-833-950-0062 (Canada toll free)
CODE 727873
WEBCAST https://events.q4inc.com/attendee/747515026
An archived webcast will also be available on the Company s Investor Relations site under the Events &
Cybin is a leading ethical biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, on a mission to
create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in the United States, United Kingdom and Ireland. The Company is focused on
progressing Psychedelics to Therapeutics by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders.
Investor & Media Contacts:
Vice President, Investor Relations
Tim Regan/Scott Eckstein
KCSA Strategic Communications
Communications, Inc.
Last updated: Nov 9, 2021